# Phase 2 Esophageal Squamous Cell Carcinoma trials: 90 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 90 trials in phase 2 for Esophageal Squamous Cell Carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Esophageal Squamous Cell Carcinoma trials: 90 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/esophageal-squamous-cell-carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 90
- Recruiting or not yet: 90
- Read on: November 19, 2026

## Trials

The 25 newest of 90, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07939204 | A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced... | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939204) |
| September 23, 2026 | NCT07836049 | PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC | Vanderbilt-Ingram Cancer Center | Phase 2 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836049) |
| September 21, 2026 | NCT07830355 | Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodes | Shanghai Chest Hospital | Phase 2 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830355) |
| September 16, 2026 | NCT07823270 | Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma | Hebei Medical University Fourth Hospital | Phase 2 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823270) |
| September 10, 2026 | NCT07811752 | Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer | Shanghai Chest Hospital | Phase 2 | Recruiting | Esophageal Squamous Cell Carcinoma | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811752) |
| September 2, 2026 | NCT07799077 | Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell... | Hebei Medical University Fourth Hospital | Phase 2 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07799077) |
| August 31, 2026 | NCT07796113 | Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC | First Affiliated Hospital Xi'an Jiaotong University | Phase 2 | Recruiting | Esophageal Squamous Cell Carcinoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796113) |
| August 7, 2026 | NCT07751055 | Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer | Sun Yat-sen University | Phase 2 | Recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751055) |
| July 29, 2026 | NCT07733830 | Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Recruiting | Esophageal Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733830) |
| July 29, 2026 | NCT07733180 | A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC | BeOne Medicines | Phase 2 | Recruiting | Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733180) |
| July 22, 2026 | NCT07721103 | Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721103) |
| July 16, 2026 | NCT07709533 | An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy... | Sun Yat-sen University | Phase 2 | Not yet recruiting | Valid MeSH Conditions | 347 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709533) |
| July 14, 2026 | NCT07701681 | Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell... | Sun Yat-sen University | Phase 2 | Not yet recruiting | ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC)... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07701681) |
| July 14, 2026 | NCT07700667 | SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Esophageal Squamous Cell Carcinoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07700667) |
| July 13, 2026 | NCT07699185 | Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma | Tongji Hospital | Phase 2 | Recruiting | Esophageal Squamous Cell Carcinoma | 336 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07699185) |
| July 7, 2026 | NCT07688291 | A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After... | Beijing GoBroad Hospital | Phase 2 | Not yet recruiting | Esophageal Squamous Carcinoma Cell | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07688291) |
| July 7, 2026 | NCT07686926 | Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686926) |
| July 1, 2026 | NCT07678580 | Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | Tang-Du Hospital | Phase 2 | Not yet recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678580) |
| June 10, 2026 | NCT07638436 | Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | Sun Yat-sen University | Phase 2 | Recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638436) |
| June 3, 2026 | NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or... | GV20 Therapeutics | Phase 2 | Not yet recruiting | Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and... | 227 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623642) |
| June 1, 2026 | NCT07618910 | Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC | Tang-Du Hospital | Phase 2 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07618910) |
| May 19, 2026 | NCT07595770 | Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595770) |
| April 30, 2026 | NCT07559045 | Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell... | Second Affiliated Hospital of Zunyi Medical University | Phase 2 | Recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559045) |
| April 28, 2026 | NCT07554521 | A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or... | BeOne Medicines | Phase 2 | Recruiting | Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07554521) |
| April 9, 2026 | NCT07519486 | Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC | Sichuan University | Phase 2 | Recruiting | Esophageal Squamous Cell Carcinoma, Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519486) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sun Yat-sen University | 7 |
| Tianjin Medical University Cancer Institute and Hospital | 7 |
| Tang-Du Hospital | 5 |
| Shanghai Chest Hospital | 5 |
| Hebei Medical University Fourth Hospital | 5 |
| Fudan University | 3 |
| Zhejiang Cancer Hospital | 3 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 3 |
| Sichuan University | 3 |
| Fujian Cancer Hospital | 3 |
| Fujian Medical University Union Hospital | 2 |
| The First People's Hospital of Changzhou | 2 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 2 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| Peking University | 2 |
| National Taiwan University Hospital | 2 |
| The First Affiliated Hospital of Zhengzhou University | 2 |
| Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 2 |
| Shanghai Zhongshan Hospital | 2 |
| Peking University People's Hospital | 1 |
| Anhui Provincial Hospital | 1 |
| Mayo Clinic | 1 |
| First Affiliated Hospital Xi'an Jiaotong University | 1 |
| Harbin Medical University | 1 |
| China Medical University Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 68 |
| United States | 6 |
| Taiwan | 5 |
| Japan | 3 |
| Australia | 2 |
| Canada | 2 |
| Germany | 2 |
| Italy | 2 |
| South Korea | 2 |
| United Kingdom | 2 |
| France | 2 |
| Brazil | 1 |
| Vietnam | 1 |
| Belgium | 1 |
| Hungary | 1 |
| Netherlands | 1 |
| Norway | 1 |
| Spain | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B industrial and machine companies in the United States](https://specstream.ai/data/businesses/b2b-industrial-and-machine-companies/united-states)
- [Comfort food restaurants in the United States](https://specstream.ai/data/businesses/comfort-food-restaurants/united-states)
- [Filipino restaurants in the United States](https://specstream.ai/data/businesses/filipino-restaurants/united-states)
- [Israeli restaurants in the United States](https://specstream.ai/data/businesses/israeli-restaurants/united-states)
- [Painting contractors in the United States](https://specstream.ai/data/businesses/painting-contractors/united-states)
- [Septic services in the United States](https://specstream.ai/data/businesses/septic-services/united-states)
